Ellen Neylon

Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies

Owen A. O’Connor, Steven M. Horwitz, Paul A. Hamlin et al. · Journal of Clinical Oncology · 2009 · 183 citations

Medicine, Pharmacology, Pharmacotherapy +17

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma

Owen A. O’Connor, Paul A. Hamlin, Carol S. Portlock et al. · British Journal of Haematology · 2007 · 92 citations

Medicine, Pharmacology, Pharmacotherapy +16

Patients with chemotherapy‐refractory mantle cell lymphoma experience high response rates and identical progression‐free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial

Owen A. O’Connor, Craig H. Moskowitz, Carol S. Portlock et al. · British Journal of Haematology · 2009 · 83 citations

Medicine, Oncology, Pharmacotherapy +16

Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma

Jennifer E. Amengual, Sean Clark-Garvey, Matko Kalac et al. · Blood · 2013 · 60 citations

Medicine, Cancer Biology, Oncology +15

Drug‐induced cutaneous vasculitis in patients with non‐Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?

John F. Gerecitano, André Goy, Barbara MacGregor‐Cortelli et al. · British Journal of Haematology · 2006 · 54 citations · Full text

Medicine, Dermatology, Pharmacology +14